secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-05-11T20:02:12+00:00
Accession:  0001193125-26-216709
Event type: debt
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian raises ~$359M via $250M convertible notes and $117M equity offering
----------------------------------------------------------------------------

- Issued $250M aggregate principal of 1.75% Convertible Senior Notes due 2032; initial conversion price ~$24.65/share.
- Equity offering of 7,352,942 shares at $17.00/share, netting ~$117M.
- Combined net proceeds ~$359M; to repay Hercules Capital debt, fund thyroid eye disease franchise expansion, and R&D.
- Both offerings closed May 11, 2026; underwriters' over-allotments exercised in full.
- Notes are unsecured, mature May 15, 2032, with semi-annual interest starting Nov 15, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/0001193125-26-216709-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526216709/d154062d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-216709

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer